Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CanBas Co. Ltd.

www.canbas.co.jp

Latest From CanBas Co. Ltd.

Positive Phase II for Polaris lead product in mesothelioma

Privately held biopharmaceutical firm Polaris Group has reported positive Phase II results for its lead product, anticancer ADI-PEG 20, in malignant pleural mesothelioma (MPM), what looks to be its second indication.

Cancer Australia

CanBas backing NSCLC candidate despite mixed results

The Japanese venture CanBas is pressing ahead with plans for a Phase III clinical trial for its lead development project CBP501 in non-small cell lung cancer (NSCLC), despite mixed preliminary efficacy results in a Phase II study in this setting.

Cancer Japan

Takeda and Japanese venture end oncology research alliance

Takeda and the Japanese bioventure CanBas have terminated a global oncology R&D collaboration which was focusing on a novel therapy for lung cancer and mesothelioma.

Cancer Japan

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2009

Thanks to the return of the initial public offering and a strong market for follow-ons, money from public investors made a huge comeback during the third quarter of 2009. The merger and acquisition scorecard totaled $17.3 billion from 22 transactions--four of which topped the billion-dollar mark. And in alliances, most notable was Johnson & Johnson and Elan Corp. PLC's joint venture, which will acquire all of the assets and rights to Elan's Alzheimer's Immunotherapy Program.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • CanBas Co. Ltd.
  • Senior Management
  • Takumi Kawabe, MD, PhD, Pres. & CEO
  • Contact Info
  • CanBas Co. Ltd.
    Phone: (81) 55 954 3666
    9 Tooriyoko-cho
    Numazu
    Shizuoka, 410-0891
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register